LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma

This study tests a combination of three drugs — lurbinectedin, ipilimumab (Yervoy), and nivolumab (Opdivo) — in patients with advanced soft tissue sarcoma (a cancer of the connective tissues like muscle, fat, or tendons). The Phase 1 part looks at safety in previously treated patients; Phase 2 looks at effectiveness in newly diagnosed patients. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic soft tissue sarcoma - Phase 1: You have received prior treatment; Phase 2: You have not received prior treatment - You have at least one measurable tumor on scans - Your physical performance is good (ECOG 0–1) - Your liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if...** - You have untreated brain metastases or cancer in the fluid around the brain - You have an active autoimmune disease - You have had prior immunotherapy with checkpoint inhibitors (anti-CTLA-4 or anti-PD-1) - You have inflammatory bowel disease, HIV, hepatitis B or C - You are pregnant or breastfeeding - You have significant heart disease - You have a history of heavy alcohol abuse Talk to your doctor to see if this trial is right for you.